JLL has announced the further strengthening of its national life science platform as part of the global real estate services firm’s continued investment in a dedicated, market-leading business line focused on supporting investors and tenants in the multi-billion-dollar sector.
Thomas Burrus has joined JLL as an associate vice president with a focus on business development in the life science and healthcare arena. He will concentrate on the New York metropolitan area and work under the leadership of John Cahill, senior vice president of JLL’s Northeast Life Sciences Practice Group.
According to JLL, the presence of leading technology firms, world renowned medical research centers, top-ranked academic institutions and large successful pharmaceutical and biotechnology companies position New York City as one of the most sought-after emerging life science clusters in the nation. Last year, tenants leased a record amount of new space as both the city and state pushed major initiatives designed to create jobs and establish New York as the global leader in the biotech sector.
“New York’s life science industry is emerging as a contender to the nation’s established hubs,” said Cahill. “As the supply of lab space continues to grow, and the commercialization in cell and gene therapy, customized medicine and translational medicine pick up speed, Tom and Kevin will have a pivotal role in our work with innovative life science companies who demand best-in-class real estate solutions.”
Burrus joined JLL from Newmark, where he served in a real estate advisory capacity nationally and as a tenant representative working with leading life science tenants in the New York metropolitan area. Among several high-profile transactions, he represented Blue Matter Consulting, a leading strategic consulting firm serving the life sciences industry, in a headquarters lease at 909 Third Ave. He also arranged a headquarters transaction on behalf of a virtual behavior healthcare company, AbleTo, at 320 West 37th St.